Skip to main content

Table 5 Candidate genes involved in phenotypic response to afatinib treatment

From: Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

a) Genes potentially involved in reduction of motility after afatinib treatment

SERPINE1

HBEGF

F3

ITGA2

CXCL8

HAS2

PLPP3

SPRY2

F2RL1

PTGS2

CYR61

CXCL1

SEMA6D

ETS1

b) Genes potentially involved in induction of apoptosis after afatinib treatment

BAX

BBC3

BCLAF1

CAV1

E2F1

FADD

FAF1

FAS

GSN

HYAL2

IL19

IL20RA

INHBB

LCK

LGALS9

NACC2

NF1

NFATC4

NKX3–1

PAK2

PARK7

PDCD5

PDIA3

PEA15

PPIF

PPP2R1B

PPP3CC

PRKRA

SFN

SFPQ

SKIL

SLC9A3R1

SMAD3

STK4

TGFBR1

TP73

TPD52L1

YWHAB

YWHAE

YWHAG

YWHAH

YWHAQ

YWHAZ

ZNF205

      
  1. Genes that were regulated in MKN1 cells after 4 h afatinib and trastuzumab + afatinib treatment and were assigned to the biological function “positive regulation of cell motility” were selected (a). Genes that were regulated in NCI-N87 but not in MKN1 and MKN7 cells after 24 h afatinib and trastuzumab + afatinib treatment and were assigned to the biological function “positive regulation of apoptotic signaling pathway” were selected (b). Italics typeface indicates downregulation and bold typeface upregulation